» Articles » PMID: 38814397

Electroporation of MRNA As a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins

Overview
Specialty Molecular Biology
Date 2024 May 30
PMID 38814397
Authors
Affiliations
Soon will be listed here.
Abstract

Electroporation (EP) of mRNA into human cells is a broadly applicable method to transiently express proteins of choice in a variety of different cell types. We have spent more than two decades to optimize and adapt this method, first for antigen-loading of dendritic cells (DCs) and subsequently for T cells, B cells, bulk PBMCs, and several cell lines. In this regard, antigens were introduced, processed, and presented in context of MHC class I and II. Next to that, functional proteins like adhesion receptors, T-cell receptors (TCRs), chimeric antigen receptors (CARs), constitutively active signal transducers (i.e. caIKK), and others were successfully expressed. We have also established this protocol under full GMP compliance as part of a manufacturing license to produce mRNA-electroporated DCs and mRNA-electroporated T cells for therapeutic applications in clinical trials. Therefore, we here want to share our universal mRNA electroporation protocol and the experience we have gathered with this method. The advantages of the transfection method presented here are: (1) easy adaptation to different cell types; (2) scalability from 10 to approximately 10 cells per shot; (3) high transfection efficiency (80-99%); (4) homogenous protein expression; (5) GMP compliance if the EP is performed in a class A clean room; and (6) no transgene integration into the genome. The provided protocol involves: OptiMEM as EP medium, a square-wave pulse with 500 V, and 4 mm cuvettes. To adapt the protocol to differently sized cells, simply the pulse time has to be altered. Thus, we share an overview of proven electroporation settings (including recovery media), which we have established for various cell types. Next to the basic protocol, we also provide an extensive list of hints and tricks, which, in our opinion, are of great value for everyone who intends to use this transfection technique.

References
1.
Gehl J . Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand. 2003; 177(4):437-47. DOI: 10.1046/j.1365-201X.2003.01093.x. View

2.
Luft C, Ketteler R . Electroporation Knows No Boundaries: The Use of Electrostimulation for siRNA Delivery in Cells and Tissues. J Biomol Screen. 2015; 20(8):932-42. PMC: 4543902. DOI: 10.1177/1087057115579638. View

3.
Dullaers M, Breckpot K, Van Meirvenne S, Bonehill A, Tuyaerts S, Michiels A . Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol Ther. 2004; 10(4):768-79. DOI: 10.1016/j.ymthe.2004.07.017. View

4.
Devoldere J, Dewitte H, De Smedt S, Remaut K . Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger. Drug Discov Today. 2015; 21(1):11-25. DOI: 10.1016/j.drudis.2015.07.009. View

5.
Schaft N, Dorrie J, Thumann P, Beck V, Muller I, Schultz E . Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol. 2005; 174(5):3087-97. DOI: 10.4049/jimmunol.174.5.3087. View